|Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a …|
J Paavonen, P Naud, J Salmerón, CM Wheeler, SN Chow, D Apter, ...
The Lancet 374 (9686), 301-314, 2009
|Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of …|
J Paavonen, D Jenkins, FX Bosch, P Naud, J Salmerón, CM Wheeler, ...
The Lancet 369 (9580), 2161-2170, 2007
|Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double …|
M Lehtinen, J Paavonen, CM Wheeler, U Jaisamrarn, SM Garland, ...
The lancet oncology 13 (1), 89-99, 2012
|Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis …|
CM Wheeler, X Castellsagué, SM Garland, A Szarewski, J Paavonen, ...
The lancet oncology 13 (1), 100-110, 2012
|Young adult sequelae of adolescent cannabis use: an integrative analysis|
E Silins, LJ Horwood, GC Patton, DM Fergusson, CA Olsson, ...
The Lancet Psychiatry 1 (4), 286-293, 2014
|Fall in human papillomavirus prevalence following a national vaccination program|
SN Tabrizi, JML Brotherton, JM Kaldor, SR Skinner, E Cummins, B Liu, ...
The Journal of infectious diseases 206 (11), 1645-1651, 2012
|Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study|
SN Tabrizi, JML Brotherton, JM Kaldor, SR Skinner, B Liu, D Bateson, ...
The Lancet infectious diseases 14 (10), 958-966, 2014
|Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials|
AR Kreimer, F Struyf, MR Del Rosario-Raymundo, A Hildesheim, ...
The lancet oncology 16 (7), 775-786, 2015
|Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double …|
SR Skinner, A Szarewski, B Romanowski, SM Garland, E Lazcano-Ponce, ...
The Lancet 384 (9961), 2213-2227, 2014
|Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18|
A Szarewski, WAJ Poppe, SR Skinner, CM Wheeler, J Paavonen, P Naud, ...
International Journal of Cancer 131 (1), 106-116, 2012
|Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study|
U Jaisamrarn, X Castellsague, SM Garland, P Naud, J Palmroth, ...
PloS one 8 (11), e79260, 2013
|Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind …|
CM Wheeler, SR Skinner, MR Del Rosario-Raymundo, SM Garland, ...
The Lancet Infectious Diseases 16 (10), 1154-1168, 2016
|Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy|
LN Lewis, DA Doherty, M Hickey, SR Skinner
Contraception 81 (5), 421-426, 2010
|Adolescent and young adult HPV vaccination in Australia: achievements and challenges|
SM Garland, SR Skinner, JML Brotherton
Preventive medicine 53, S29-S35, 2011
|Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial|
ER Bahmanyar, J Paavonen, P Naud, J Salmerón, SN Chow, D Apter, ...
Gynecologic oncology 127 (3), 440-450, 2012
|“Is cancer contagious?”: Australian adolescent girls and their parents: Making the most of limited information about HPV and HPV vaccination|
SCC Robbins, D Bernard, K McCaffery, J Brotherton, S Garland, ...
Vaccine 28 (19), 3398-3408, 2010
|Very low prevalence of vaccine human papillomavirus types among 18-to 35-year old Australian women 9 years following implementation of vaccination|
DA Machalek, SM Garland, JML Brotherton, D Bateson, K McNamee, ...
The Journal of infectious diseases 217 (10), 1590-1600, 2018
|Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the …|
D Apter, CM Wheeler, J Paavonen, X Castellsagué, SM Garland, ...
Clinical and Vaccine Immunology 22 (4), 361-373, 2015
|Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation|
A Szarewski, SR Skinner, SM Garland, B Romanowski, TF Schwarz, ...
The Journal of infectious diseases 208 (9), 1391-1396, 2013
|Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study|
S Rachel Skinner, CM Wheeler, B Romanowski, X Castellsagué, ...
International journal of cancer 138 (10), 2428-2438, 2016